Overview: A New Mechanism Behind Osimertinib Resistance in EGFR-Mutant NSCLC Osimertinib has transformed the treatment landscape for patients with EGFR-mutant non-small cell lung cancer (NSCLC). Yet resistance remains a major hurdle. A recent study identifies a non-genetic mechanism: the membrane protein IFITM3 interacts with MET to activate the PI3K-AKT signaling axis, enabling tumor cells to…